A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas
Phase of Trial: Phase I/II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs TRC 102 (Primary) ; Temozolomide
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Lymphoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 06 Jun 2017 Results (n=15) from the expansion phase of the trial, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 03 Sep 2016 Planned End Date changed from 1 Feb 2017 to 1 Dec 2019.
- 03 Sep 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2019.